Daniel O’Day, the CEO of Gilead.
Ruben Sprich / Reuters
Gilead Sciences just announced plans for two late-stage clinical studies to test a treatment for COVID-19, the disease caused by the growing coronavirus outbreak.
The studies will enroll approximately 1,000 patients with confirmed cases of COVID-19 across Asian countries and other areas with high rates of cases, the company said on Wednesday.
The two trials will test an antiviral medication called remdesivir, a therapy that was previously tested against the Ebola virus.
A Gilead executive said other studies of remdesivir in China would “give us a more expansive breadth of data globally on the drug’s profile in a short amount of time.”
The $95 billion biotech Gilead Sciences is accelerating its effort to test a